Ambrx Biopharma, Inc.

Richard DiMarchi has had a ringside seat throughout the 40 years from when GLP-1s were first discovered to becoming one of the most important driving forces in the pharmaceutical industry thus far. He

Johnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is

Merger-and-acquisition activity during the first quarter of 2024 was not likely to match the bustling pace of Q4 2023, when the aggregate dollar amount committed to acquisitions topped $52bn and nearl

With the oft-cited patent cliff looming, big pharma companies are still looking to replenish pipelines. For many, partnering represents an important avenue to do so with its more limited financial ris